Andon Health Co.Ltd(002432) once again fell into a negative crisis.
On March 1, Andon Health Co.Ltd(002432) publicly responded to the rumor that “the United States is ready to cancel the authorization for emergency use of ihealth products”, saying that the company has no such situation at present, and the rumor has no factual basis. If the rumor misleads and adversely affects the listed company and the capital market, it will be investigated for responsibility through legal means.
Previously, it was reported that the above rumors came from experts from Hangzhou Biotest Biotech Co.Ltd(688767) who maliciously spread rumors about their competitor Andon Health Co.Ltd(002432) . In response to this statement, Hangzhou Biotest Biotech Co.Ltd(688767) denied that the experts participating in the above teleconference were the personnel of the company, and said they were not involved in the rumor Zheshang Securities Co.Ltd(601878) Research Institute subsequently responded to the Chinese reporter of the securities firm, saying that the information or opinions expressed by relevant experts in the teleconference belong to their personal views and do not represent the views of the Research Institute.
Affected by the above negative news, Andon Health Co.Ltd(002432) 3 on March 1, the share price fell 9.48% to close at 58.18 yuan / share, with a turnover of 5.282 billion yuan. At the same time, according to choice data, Andon Health Co.Ltd(002432) also became the single stock with the largest net outflow of the main A shares on that day, with a total outflow of 1.3 billion yuan. Meanwhile, the net outflow of super large orders and large orders were 1.048 billion yuan and 252 million yuan respectively.
Stop using authorization in the United States?
Recently, it is rumored on the Internet that some experts said on the teleconference of securities companies that because Andon Health Co.Ltd(002432) the ihealth test kit has low detection sensitivity, inaccurate test results and low reliability, the U.S. Food and Drug Administration (FDA) is ready to cancel the authorization for the emergency use of ihealth.
If this rumor is true, Andon Health Co.Ltd(002432) previous purchase contracts with the United States with a total value of more than 10 billion yuan may become invalid. Investors frequently asked questions on the interactive platform of Shenzhen Stock Exchange and asked Andon Health Co.Ltd(002432) to respond positively to “whether the US government, FDA or other relevant subjects have questioned the detection sensitivity or quality of ihealth antigen detection kit, and whether there are facts that may lead to the above-mentioned questions raised by the US side”.
in this regard, Andon Health Co.Ltd(002432) also made it clear that the company has no such situation at present, and the rumor has no factual basis. If the rumor misleads and adversely affects the listed company and the capital market, it will be investigated for responsibility through legal means
Andon Health Co.Ltd(002432) also mentioned that at present, the company’s covid-19 antigen detection kit products have been sold on ihealth’s official website in Hong Kong, which is the beginning of its full support for epidemic prevention in Hong Kong, and there are still many uncertain factors in the market.
At the same time, relevant rumors also mentioned that the experts who attacked Andon Health Co.Ltd(002432) in the teleconference came from Hangzhou Biotest Biotech Co.Ltd(688767) . In this regard, Hangzhou Biotest Biotech Co.Ltd(688767) also quickly responded that the experts participating in the teleconference were not its company personnel, and the company did not participate in the rumor Andon Health Co.Ltd(002432) incident.
In addition, Hangzhou Biotest Biotech Co.Ltd(688767) also said that it had communicated with Zheshang Securities Co.Ltd(601878) and was currently verifying the identity of the participants.
Institute response: personal views of experts
The Chinese reporter of securities company also asked Zheshang Securities Co.Ltd(601878) for confirmation on this matter
According to the response of Zheshang Securities Co.Ltd(601878) Research Institute, on February 27, the Institute organized an expert exchange teleconference with the theme of “covid-19 antigen detection industry analysis”. The teleconference invited experts with relevant industry background and was only open to the customers of its contracting institutions.
In the question and exchange link after the above telephone meeting, the experts involved mentioned ” Andon Health Co.Ltd(002432) ” when discussing professional issues. The relevant comments made by the experts only involve professional discussion, and their views and comments come from the personal understanding of the experts themselves. The information or opinions expressed by experts in the teleconference belong to their personal views and do not represent the research views of Zheshang Securities Co.Ltd(601878) Research Institute.
Zheshang Securities Co.Ltd(601878) Research Institute said that the current content of online communication is taken out of context, which has affected the reputation of Zheshang Securities Co.Ltd(601878) and relevant companies. Relevant platforms and people should immediately delete false information and improper remarks and stop the communication. Without Zheshang Securities Co.Ltd(601878) authorization, no one has the right to disclose any information related to the telephone, including but not limited to text, video and audio.
“We reserve the right to pursue legal responsibility for violations of the above requirements.” Zheshang Securities Co.Ltd(601878) Institute emphasized.
One day share price fell 9.5%
A stone stirs thousands of waves. Affected by the above negative news, Andon Health Co.Ltd(002432) 3 on March 1, the share price fell 9.48% and finally closed at 58.18 yuan / share, with a turnover of 5.282 billion yuan.
According to choice data, Andon Health Co.Ltd(002432) on that day, the net outflow of the main force totaled 1.3 billion yuan, making it the single stock with the largest net outflow of the main force of A-Shares on that day. At the same time, the net outflow of super large orders and large orders were 1.048 billion yuan and 252 million yuan respectively.
In fact, since November 7 last year, Andon Health Co.Ltd(002432) disclosed that the U.S. subsidiary ihealth home covid-19 self-test kit was authorized by the FDA for emergency use, the company’s share price has been rising on the cableway. Since then, a total of 33 trading boards have been harvested, and the share price once soared to nearly 89 yuan / share from 6.39 yuan / share on November 8 last year, becoming a “ten times Bull Stock” to the letter.
Not long ago, on January 27, Andon Health Co.Ltd(002432) revealed that its U.S. subsidiary signed a change contract with ACC (U.S. Army contract management command) on the original procurement contract, and the total contract amount increased from US $1.275 billion to US $1.775 billion (about RMB 11.226 billion).
According to the announcement, the performance of the above contract will have a positive impact on the operating revenue and operating profit of Andon Health Co.Ltd(002432) 2022. The latest announcement shows that as of February 15 local time, ACC has paid a total of US $465 million, or about RMB 2.95 billion, to Andon Health Co.Ltd(002432) US subsidiaries, all of which have arrived on February 16 local time.
However, the company has the right to suspend the contract at any time due to changes in the contract, force majeure and other factors in the supply chain, which may affect the company’s ability to perform the contract as scheduled or due to changes in the contract, force majeure and other factors.
Stock price speculation continues to be questioned
It is worth noting that perhaps the stock price has risen too fast. Since 2022, Andon Health Co.Ltd(002432) has been frequently questioned as “hyping the stock price”. Under the influence of multiple negative news, its latest closing price has fallen by about 35% compared with the range high of 88.88 yuan / share on January 18.
On February 22, the Shenzhen Stock Exchange issued a supervision letter to Andon Health Co.Ltd(002432) stating that in the announcement of listed companies on January 7, the information disclosure of the experimental results of “the performance test of the household self-test OTC kit for ihealth covid-19 antigen against Omicron variant virus” arranged by FDA was incomplete.
In addition, during the previous consecutive stock price changes, Andon Health Co.Ltd(002432) in the reply of interactive easy platform and the record form of investor relations activities published, there were many inaccurate and incomplete situations, especially involving the sales volume of Andon Health Co.Ltd(002432) covid-19 detection reagent on Amazon US website, the proportion of shares held by US subsidiaries and other sensitive information.
The chairman and the Secretary of the board of directors of Tianjin Securities Regulatory Commission decided not to disclose the above-mentioned information due to the announcement of the board of directors of Tianjin Securities Regulatory Commission on February 14 Andon Health Co.Ltd(002432) said it would actively rectify in strict accordance with the regulatory requirements, strengthen the learning of relevant personnel on securities laws and regulations, strengthen the awareness of standardized operation, strengthen internal control and information disclosure management, and effectively improve the standardized operation level and information disclosure quality of the company.
Earlier, the Shenzhen Stock Exchange also asked directly in the attention letter on January 12, asking Andon Health Co.Ltd(002432) to explain whether the disclosure of its announcement on January 7 was true, accurate and complete, whether there were misleading statements or major omissions, and whether it was clear, appropriate and easy to understand; And whether the contents contained in the record of investor relations activities published on January 10 are cautious and objective, and whether there are exaggerated publicity and misleading tips to cater to the concept of market hot spots and hype the stock price.
In response, Andon Health Co.Ltd(002432) responded that it specifically emphasized the possible reduction of antigen detection sensitivity in the announcement, and would strengthen the control over the integrity of the wording of the announcement in the future, but it did not have the behavior and motivation to hype the stock price through information disclosure, and there was no change in the stock price in the three consecutive trading days since the date of the announcement.
On January 9, Andon Health Co.Ltd(002432) put forward the “suggestions on using family self-test box to realize Omicron covid-19 epidemic prevention 1 + 1” to Tianjin epidemic prevention and control headquarters. In response to the question, he disclosed the full text of the suggestions at that time and explained the above suggestions. The relevant departments in Tianjin are studying the scheme. The content is not exaggerated or misleading, nor is it motivated by hot spots.
According to the performance notice issued on Andon Health Co.Ltd(002432) 119, its net profit in 2021 is expected to grow from 900 million to 1 billion 200 million yuan, up 271.4% to 395.19% over the same period, mainly because the sales of New Coronavirus (SARS-CoV-2) antigen self testing OTC kit products in the US market has increased significantly.
“In 2021, the company’s operating performance mainly depends on covid-19 testing reagent. There is major uncertainty whether the future performance can continue to maintain rapid growth.” Andon Health Co.Ltd(002432) said that this mainly depends on the progress of covid-19 epidemic prevention and control in the United States, the selection of covid-19 testing products in the United States, product market competitiveness and channel sales ability, as well as the future development of conventional business, and investors need to pay attention to investment risks.
